T3 Pharmaceuticals

T3 Pharmaceuticals is a private, pre-revenue biotech pioneering a novel bacterial cancer therapy platform. Leveraging a proprietary Type 3 Secretion System (T3SS) technology, the company engineers non-pathogenic bacteria to selectively invade solid tumors and deliver immunomodulatory or cytotoxic payloads directly into cancer cells. With a seasoned leadership team combining deep scientific expertise in microbiology and immunology with extensive clinical development experience from major pharma, T3 is positioned to advance a new class of targeted oncolytic agents. The company is headquartered in the Basel life sciences hub and is supported by a board and advisory network with strong ties to Boehringer Ingelheim and leading academic institutions.

Engineered live bacterial therapy platform using a hypoxia-activated Type 3 Secretion System (T3SS) to deliver therapeutic protein payloads directly into the cytoplasm of solid tumor cells.

T3 competes in the oncolytic therapy space, which is dominated by viral platforms like Imlygic (talimogene laherparepvec). It faces competition from other bacterial therapy developers (e.g., BioNTech's iNeST platform, although not bacterial) and companies developing intratumoral immunotherapies. Its differentiation lies in the precise, hypoxia-triggered, intracellular protein delivery via the T3SS.